Peter Luo

441 total citations
25 papers, 325 citations indexed

About

Peter Luo is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Peter Luo has authored 25 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Peter Luo's work include Cancer Immunotherapy and Biomarkers (10 papers), CAR-T cell therapy research (8 papers) and Peptidase Inhibition and Analysis (6 papers). Peter Luo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), CAR-T cell therapy research (8 papers) and Peptidase Inhibition and Analysis (6 papers). Peter Luo collaborates with scholars based in United States, China and South Korea. Peter Luo's co-authors include Guizhong Liu, Amanda J. Pickard, Frank J. Piscotta, Justin R. Cross, Arka Rao, Sun M. Han, Michael Boyce, Louis Cohen, Sean F. Brady and Dominic A. Colosimo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Peter Luo

19 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Luo United States 8 185 77 72 39 37 25 325
Alexandria K. D’Souza United States 11 287 1.6× 44 0.6× 69 1.0× 20 0.5× 23 0.6× 11 392
J. David Knox Canada 10 262 1.4× 34 0.4× 92 1.3× 13 0.3× 15 0.4× 25 547
Yingying Zhao China 12 185 1.0× 92 1.2× 17 0.2× 38 1.0× 13 0.4× 27 379
Rachid Zagani United States 9 227 1.2× 82 1.1× 46 0.6× 6 0.2× 31 0.8× 11 402
Robert Schultz‐Heienbrok Germany 7 326 1.8× 25 0.3× 50 0.7× 12 0.3× 68 1.8× 7 439
Yinjie Zhang China 9 187 1.0× 85 1.1× 39 0.5× 16 0.4× 12 0.3× 22 337
Edgar Fernández Spain 9 138 0.7× 237 3.1× 90 1.3× 21 0.5× 18 0.5× 9 474
Caifeng Chen China 11 149 0.8× 113 1.5× 61 0.8× 21 0.5× 8 0.2× 24 328
Samir K. Nath United States 11 337 1.8× 40 0.5× 31 0.4× 13 0.3× 32 0.9× 17 520
Udit Dalwadi Canada 12 276 1.5× 48 0.6× 28 0.4× 11 0.3× 52 1.4× 18 382

Countries citing papers authored by Peter Luo

Since Specialization
Citations

This map shows the geographic impact of Peter Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Luo more than expected).

Fields of papers citing papers by Peter Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Luo. The network helps show where Peter Luo may publish in the future.

Co-authorship network of co-authors of Peter Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Luo. A scholar is included among the top collaborators of Peter Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Luo. Peter Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Yongsheng, Yan Huang, Yuanyuan Zhao, et al.. (2025). Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors. iScience. 28(5). 112497–112497. 2 indexed citations
2.
3.
Li, Daneng, Sun Young Kim, Hee Kyung Kim, et al.. (2025). Update of phase 1b/2 study of muzastotug (ADG126, an anti-CTLA-4 SAFEbody) in combination with pembrolizumab in advanced/metastatic MSS CRC.. Journal of Clinical Oncology. 43(4_suppl). 193–193. 1 indexed citations
4.
Luo, Peter, Christopher Chaney, Denise K. Marciano, et al.. (2025). Zonal endothelial cell heterogeneity underlies murine renal vascular development. Angiogenesis. 28(4). 57–57.
5.
Li, Daneng, Sun Young Kim, Manish Patel, et al.. (2025). Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab: Updated results of phase 1b/2 study in advanced MSS CRC.. Journal of Clinical Oncology. 43(16_suppl). 3579–3579.
6.
Ma, Yuxiang, Fan Luo, Yang Zhang, et al.. (2024). Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin’s lymphoma. Cell Reports Medicine. 5(2). 101414–101414. 8 indexed citations
7.
8.
Luo, Peter, Xiaowu Gu, Christopher Chaney, Thomas J. Carroll, & Ondine Cleaver. (2023). Stromal netrin 1 coordinates renal arteriogenesis and mural cell differentiation. Development. 150(22). 7 indexed citations
9.
10.
Liu, Guizhong & Peter Luo. (2023). Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy. Frontiers in Immunology. 14. 1208788–1208788. 14 indexed citations
11.
12.
Zhao, Hongyun, Shun Zheng, Yi Ma, et al.. (2021). 43P Assessment of biomarker kinetics for ADG106 (anti-CD137 agonist) as monotherapy or combined with toripalimab. Annals of Oncology. 32. S1389–S1390. 1 indexed citations
13.
14.
Richardson, Gary, Francis Parnis, Anis Hamid, et al.. (2021). 137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors. Annals of Oncology. 32. S1436–S1437. 1 indexed citations
15.
Liu, Guizhong, et al.. (2021). Abstract 1853: A novel anti-CTLA-4 checkpoint inhibitor prodrug to address on-target off-tumor toxicity for cancer immunotherapy. Cancer Research. 81(13_Supplement). 1853–1853. 2 indexed citations
16.
Colosimo, Dominic A., Peter Luo, Frank J. Piscotta, et al.. (2019). Mapping Interactions of Microbial Metabolites with Human G-Protein-Coupled Receptors. Cell Host & Microbe. 26(2). 273–282.e7. 132 indexed citations
17.
18.
Luo, Peter & Michael Boyce. (2019). Directing Traffic: Regulation of COPI Transport by Post-translational Modifications. Frontiers in Cell and Developmental Biology. 7. 190–190. 17 indexed citations
19.
Luo, Peter, et al.. (2018). A Novel Glycoproteomics Workflow Reveals Dynamic O-GlcNAcylation of COPγ1 as a Candidate Regulator of Protein Trafficking. Frontiers in Endocrinology. 9. 606–606. 12 indexed citations
20.
Luo, Peter, Liuyang Wang, Elizabeth Theusch, et al.. (2017). Human genetic variation in VAC14 regulates Salmonella invasion and typhoid fever through modulation of cholesterol. Proceedings of the National Academy of Sciences. 114(37). E7746–E7755. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexandria K. D’Souza Breakdown of academic impact, for papers by J. David Knox Breakdown of academic impact, for papers by Yingying Zhao Breakdown of academic impact, for papers by Rachid Zagani Breakdown of academic impact, for papers by Robert Schultz‐Heienbrok Breakdown of academic impact, for papers by Yinjie Zhang Breakdown of academic impact, for papers by Edgar Fernández Breakdown of academic impact, for papers by Caifeng Chen Breakdown of academic impact, for papers by Samir K. Nath Breakdown of academic impact, for papers by Udit Dalwadi
Rankless by CCL
2026